Therapy is one of the most effective treatments for depression and anxiety. Cognitive behavioral therapy (CBT), dialectical behavior therapy (DBT), psychodynamic therapy, and other evidence-based modalities have decades of research supporting their efficacy. But what happens when a patient has been in therapy for months—or even years—and their symptoms haven’t meaningfully improved?
As a board-certified psychiatrist who works collaboratively with therapists across Massachusetts, I see this pattern regularly. A dedicated patient attends weekly sessions, does the homework, practices the coping skills—and yet the depression or anxiety persists. The patient feels stuck. The therapist feels stuck. And both may wonder whether something else is needed.
The answer, in many cases, is that medication evaluation should be part of the conversation. This isn’t about replacing therapy—it’s about recognizing when a combined approach through split treatment can unlock progress that talk therapy alone cannot achieve.
The term “treatment-resistant” gets used frequently in psychiatry, but it’s worth clarifying what it actually means in clinical practice. Treatment-resistant depression is generally defined as depression that hasn’t responded adequately to at least two trials of antidepressant medication at therapeutic doses for adequate duration (typically 6-8 weeks each). But in the therapy context, we can think of it more broadly: when a patient’s symptoms have plateaued despite consistent, quality therapeutic work.
For anxiety disorders, resistance to treatment may present differently. A patient might develop excellent cognitive awareness of their anxiety patterns through therapy but still experience debilitating physical symptoms—racing heart, muscle tension, insomnia, gastrointestinal distress—that cognitive strategies alone cannot fully address.
This is where the neurobiology matters. Depression and anxiety involve measurable changes in neurotransmitter systems, neural circuitry, and stress hormone regulation. While therapy can absolutely produce neurobiological changes (neuroimaging studies have confirmed this), some patients’ brain chemistry requires pharmacological intervention to create the foundation upon which therapy can build.
Based on my clinical experience and the research literature, here are the key indicators that a patient may benefit from a psychiatric medication evaluation. Therapists: if you’re seeing three or more of these in a patient, it’s time to have the medication conversation.
Evidence-based therapies like CBT typically show meaningful symptom improvement within 8-16 sessions. If a patient has been engaged in consistent therapy for 3+ months with no clinically significant improvement on standardized measures (PHQ-9 for depression, GAD-7 for anxiety), biological factors may be limiting their response.
When depression manifests primarily through vegetative symptoms—severe insomnia or hypersomnia, significant appetite and weight changes, profound fatigue, psychomotor retardation—these often have strong neurobiological underpinnings that medication addresses more directly than talk therapy.
If a patient is missing work, withdrawing from relationships, neglecting self-care, or struggling with daily tasks despite therapeutic engagement, the severity level suggests medication may be necessary to stabilize symptoms enough for therapy to be effective.
A strong family history of depression, anxiety, bipolar disorder, or other psychiatric conditions—particularly if family members responded well to medication—is a significant predictor that the patient may benefit from pharmacotherapy. Genetics play a substantial role in treatment response.
Patients experiencing their third or more episode of major depression have a 90%+ likelihood of future recurrence. For recurrent depression, medication not only treats the current episode but serves a critical preventive function. The American Psychiatric Association guidelines recommend long-term maintenance medication for patients with recurrent major depressive episodes.
Comorbid anxiety and depression is extremely common and often responds particularly well to combined treatment. When both conditions are present, each can amplify the other, creating a cycle that’s difficult to break with therapy alone.
Any expression of suicidal thoughts, intent, or self-harm behavior should prompt immediate consideration of psychiatric evaluation. While therapy is essential for processing these experiences, medication can reduce the intensity and frequency of suicidal ideation, providing a critical safety net.
Panic disorder, severe somatic anxiety, and phobias with strong physiological components often benefit significantly from medication. SSRIs and SNRIs can reduce the frequency and intensity of panic attacks, while therapy addresses the cognitive and behavioral patterns that maintain anxiety.
Use this practical checklist when evaluating whether a therapy patient may benefit from a medication consultation:
If 3 or more items apply, a psychiatric medication evaluation is strongly recommended.
Many therapists hesitate to bring up medication because they worry it signals failure or undermines the therapeutic relationship. In reality, recommending a psychiatric evaluation demonstrates clinical sophistication and genuine care for the patient’s wellbeing.
Split treatment—where a therapist provides psychotherapy while a psychiatrist manages medication—is actually the gold standard for many psychiatric conditions. Here’s how it typically works:
Frame medication evaluation as adding a tool, not replacing therapy. Patients respond well to language like: “I believe in the work we’re doing together, and I want to make sure you have every advantage. A medication evaluation could give us another tool to work with—and if medication helps stabilize your symptoms, it can actually make our therapy sessions more productive.”
A comprehensive psychiatric evaluation typically includes a detailed history, symptom assessment, review of prior treatments, family history, medical history, and a discussion of medication options. At Luminous Vitality Behavioral Health, initial evaluations are 60 minutes—enough time for a thorough assessment and collaborative treatment planning.
The best outcomes in split treatment come from active communication between therapist and psychiatrist. This includes sharing treatment goals, discussing progress, coordinating around medication changes, and aligning on crisis management plans. A good psychiatrist values this collaboration and actively seeks it.
For therapists interested in establishing a referral relationship, our therapist referral page outlines how we work with referring clinicians. We also published a practical guide: When to Refer Your Therapy Client for Psychiatric Medication.
If you’re a patient reading this because you’ve been in therapy and are wondering whether medication might help, here are some important things to understand:
Depression and anxiety are complex conditions with biological, psychological, and social components. Therapy addresses the psychological and social dimensions powerfully. Medication addresses the biological dimension. Using both is not failure—it’s comprehensive treatment.
Many patients use medication for a defined period—sometimes 6-12 months for a first episode, sometimes longer for recurrent conditions. The decision about duration is individualized and made collaboratively between you and your psychiatrist.
Today’s psychiatric medications, particularly SSRIs and SNRIs, have significantly improved side effect profiles compared to older medications. Most side effects are mild and often resolve within the first 2-4 weeks. Your psychiatrist will work with you to find the medication and dose that provides the best benefit-to-side-effect ratio.
One of the most common fears about psychiatric medication is personality change. Properly prescribed medication doesn’t change who you are—it removes the fog, the heaviness, or the constant alarm bells that depression and anxiety create, allowing your actual personality to come through more clearly.
The research strongly supports combined therapy and medication for moderate-to-severe depression and anxiety:
Patient ambivalence about medication is common and completely understandable. Many patients have heard horror stories, fear dependency, or worry about side effects. The therapist’s role isn’t to push medication but to normalize the conversation. Consider saying: “I’m not suggesting you definitely need medication—I’m suggesting we get an expert opinion so you can make a fully informed decision about your treatment options.”
A psychiatric evaluation doesn’t commit anyone to taking medication. It’s an information-gathering appointment. Many patients feel relieved to learn about their options, even if they ultimately decide not to start medication immediately.
This concern is more common than therapists admit. The reality is that medication management psychiatry visits are typically 15-30 minutes every 1-3 months—they are not therapy sessions. A psychiatrist managing medication is not replacing the therapist’s role. In fact, well-managed medication often makes therapy more effective, deepening the therapeutic work and strengthening the patient’s engagement.
The best split treatment relationships are genuinely collaborative. The therapist sees the patient weekly and has the deepest understanding of their psychological patterns. The psychiatrist brings pharmacological expertise. Together, they provide more comprehensive care than either could alone.
This is one of the most important clinical questions, and the honest answer is: it’s rarely purely one or the other. Most depression and anxiety involves both biological vulnerability and environmental triggers. The presence of situational stressors doesn’t rule out a biological component that medication could address.
A helpful framework: if situational factors are present and the patient’s symptom severity is disproportionate to their circumstances, has persisted long after the stressor resolved, or includes significant vegetative symptoms, biological factors are likely contributing. A psychiatric evaluation can help clarify this distinction.
One barrier to medication evaluation has historically been access—finding a psychiatrist with availability can take weeks or months. Telehealth has dramatically improved access to psychiatric care. Patients anywhere in Massachusetts can now schedule an evaluation without traveling to an office, taking extra time off work, or sitting in a waiting room. For therapists, this means you can refer your patient to a psychiatrist and have them evaluated quickly, keeping treatment momentum going rather than losing weeks to scheduling logistics.
Whether you’re a therapist considering a referral or a patient exploring medication options, the process is straightforward:
For therapists: Visit our therapist referral page or call our office directly. We welcome collaborative relationships and make the referral process as seamless as possible for your patients.
For patients: Talk to your therapist about whether a medication evaluation might be appropriate. If you’d like to schedule a psychiatric evaluation directly, contact Luminous Vitality Behavioral Health.
Luminous Vitality Behavioral Health is a private pay / out-of-network practice. Many patients with PPO/EPO plans receive 60-80% reimbursement. We provide superbills for easy insurance submission.
Schedule an evaluation: Call 617-841-3620 or visit luminousvitalitybh.com
Dr. Ronald Lee is a board-certified psychiatrist serving all of Massachusetts via telehealth. He specializes in medication management for depression, anxiety, ADHD, and other psychiatric conditions, working collaboratively with therapists to provide comprehensive split treatment.
Request an initial appointment by clicking the Appointment Bot to register for the patient portal--or call for help!
You are NOT financially committed to anything until you enter your payment information AND your appointment is confirmed!!
Please complete the form below for any questions. Request an Appointment for the quickest and most efficient way.
One Boston Place, 201 Washington St. Suite 2679, Boston, MA 02108
(Virtual Office Address as LVBH is Boston Based but Servicing All Areas/Residents of MA via Telemedicine)
